University of Miami
Open enrollment with an early-phase pipeline tilt
According to ClinicalTrials.gov-derived indexes, University of Miami sits in the top decile of US sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count).
University of Miami: 721 sponsored US clinical trials, 145 recruiting.
University of Miami sponsors 721 registered US clinical trials on ClinicalTrials.gov, 145 of them currently recruiting, and 430 completed. 79 of these trials are in Phase 3-4 (later-stage) and 134 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Prostate Cancer, with 10 trials.
Top-decile sponsor footprint
University of Miami ranks in the top decile of sponsors by registered trial count (#46 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.
Trial completion reliability score
430 of 515 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (83.5%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.
Open and recent trials
721 total, page 4 of 15
Tell Me More ("Dime Mas")
NCT06063083
Horizons Chronic Graft-Versus-Host-Disease Study
NCT06160986
Electronic Health Mindfulness-based Music Therapy Intervention for Patients Undergoing Allogeneic Stem Cell Transplantation
NCT05968963
Unified Protocol for Preventing Emotional and Academic Challenges in Education (U-PEACE)
NCT06056674
A Novel Therapy for Breast Cancer Survivors With Genitourinary Syndrome of Menopause
NCT05812924
Human Amnion Membrane Allograft and Early Return of Erectile Function After Radical Prostatectomy
NCT05842057
Levels of Circulating Tumor DNA as a Predictive Marker for Early Switch in Treatment for Patients With Metastatic (Stage IV) Breast Cancer
NCT05826964
Effectiveness and Safety of Embosphere Microspheres for Embolization of the Geniculate Artery for the Treatment of Pain With Known Moderate to Severe Knee Osteoarthritis
NCT05112926
Preventing Anxiety and Depression in Older Hispanics
NCT03870360
Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1
NCT07224035
Tele-Harm Reduction
NCT05208697
Database of Monochorionic Pregnancies
NCT05543499
Jump Start Plus COVID-19 Support
NCT05445518
Investigation of Prostate Artery Embolization Compared to Holmium Laser Enucleation of Prostate
NCT05155891
Lymphedema Specific PROs for Risk Assessment, Prevention and Early Detection
NCT05929001
Phenotype, Genotype and Biomarkers 2
NCT04875416
Marker Driven Selection of Patients for Prostate Biopsy and Management
NCT04240327
A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma
NCT04268498
Baby Item Learning and Development Study
NCT04267302
Developing Strategies for Effective Debridement in Patients for Venous Leg Ulcers
NCT03796793
Liraglutide Effect in Atrial Fibrillation
NCT03856632
TRIAL READY (Clinical Trial Readiness)
NCT03912987
ThRombectomy In Mild Ischemic Stroke With a Visible Intracranial veSsel Occlusion
NCT06778226
TracPatch in Total Knee Arthroplasty
NCT03466476
Phenotype, Genotype & Biomarkers in ALS and Related Disorders
NCT02327845
Randomized MRI-Guided Prostate Boosts Via Initial Lattice Stereotactic vs Daily Moderately Hypofractionated Radiotherapy
NCT02307058
PRE-Symptomatic Studies in Amyotrophic Lateral Sclerosis
NCT01508962
Radiation Hypofractionation Via Extended Versus Accelerated Therapy (HEAT) For Prostate Cancer
NCT01794403
MRI-Mapped Dose-Escalated Salvage Radiotherapy Post-Prostatectomy: The MAPS Trial
NCT01411345
Self-Help Group for the Treatment of Hoarding Disorder
NCT01585896
Nipple-Areola Complex (NAC) Irradiation After Nipple-Sparing Mastectomy and Reconstruction
NCT01208974
Zynrelef Versus Adductor Canal Block
NCT07216586
Alexis Retractor in Total Hip Arthroplasty
NCT07237737
Parent-Child Interaction Therapy (PCIT) for Children With Traumatic Brain Injury (TBI): A Stepped-Care Model
NCT06193382
Antibiotic-coated Braided Suture Study
NCT07322289
Women's Healthy Aging and Menopause; (WHAM)
NCT07314827
Consciousness Studies and Cardiovascular Health
NCT07620639
MRIdian "RADAR" Trial
NCT06077071
BRIDGES: An HIV Doula Program
NCT07664423
PLEASURE (Pleasing Lovers, Efficacy, Arousal, Satisfaction, and Uptake Research on Eroxon)
NCT07636161
e-Health Psychosocial Stress and Symptom Management (ePSMI) for Pancreatic Cancer Patients
NCT06893276
Tailored Anti-Inflammatory American Diet for Patients With Crohn's Disease
NCT07671872
PLAY2CONTROL Study
NCT07556679
Alternate Pre-med in Anti-Cluster of Differentiation 20 (CD20) Pilot Project
NCT07472413
Autologous Serum Tears With Hyaluronate vs Balanced Salt Solution for Moderate-to-Severe Dry Eye
NCT07413172
PrEP & Soccer: A Program for Pharmacy Chains to Increase PrEP Awareness and Access Among Men
NCT07263048
Emapalumab MDA5 Rapidly Progressive Interstitial Lung Disease (RP-ILD) Study
NCT07486869
eHealth Mindfulness-based Music Therapy Intervention for Patients Undergoing Stem Cell Transplantation
NCT07469592
Guardant Shield Colorectal Cancer Screening
NCT07436637
Adaptive Self-Efficacy-Based AI Coaching for Cycling
NCT07318233
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 48 |
| Phase 2 | 86 |
| Phase 3 | 18 |
| Phase 4 | 61 |
Therapeutic Areas
What is open in the University of Miami pipeline
145 recruiting of 721 indexed (20% open); 430 completed (60%).
Phase mix: 79 late (III/IV) vs 134 early (I/II) (early-phase heavy).
Top condition: Prostate Cancer (10 trials), 9 others listed.
How open-pipeline share is computed
Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.
University of Miami: open-pipeline peers nationwide
Peers matched on 721 registered trials and 20% open enrollment, not the therapeutic-area sidebar.
University of Miami sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.
Sponsors near 721 trials (± recruiting share)
- Sanofi · 713 trials · 10% recruiting
- The University of Texas Health Science Center, Houston · 732 trials · 20% recruiting
- Icahn School of Medicine at Mount Sinai · 708 trials · 23% recruiting
- Weill Medical College of Cornell University · 701 trials · 18% recruiting
Sponsors near 20% open enrollment (± trial volume)
- University of California, Irvine · 20% recruiting · 368 trials
- Endeavor Health · 20% recruiting · 94 trials
- Acera Surgical · 20% recruiting · 5 trials
- Align Technology · 20% recruiting · 5 trials
Related
What to do with this University of Miami page
721 registered trials is a research-attention snapshot, not an endorsement of University of Miami or any single study.
- 145 of University of Miami's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
- Prostate Cancer is the condition University of Miami studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Prostate Cancer trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
University of Miami pipeline card: 721 registered trials from official public datasets.Report a data error.